S
Stéphane Laurent
Researcher at University of Paris
Publications - 428
Citations - 82831
Stéphane Laurent is an academic researcher from University of Paris. The author has contributed to research in topics: Blood pressure & Arterial stiffness. The author has an hindex of 83, co-authored 424 publications receiving 75440 citations. Previous affiliations of Stéphane Laurent include University of Lausanne & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Facteurs prédictifs de mortalité et de morbidité cardiovasculaires dans l'hypertension artérielle
TL;DR: La pression pulsée centrale constitue un facteur prédictif de mortalité de toutes causes au cours of l’insuffisance rénale terminale, ce qui n’est pas le cas of the pression pulse périphérique.
Book ChapterDOI
Arterial Stiffness in Early Phases of Prehypertension
Stéphane Laurent,Pedro Cunha +1 more
TL;DR: A review of the epidemiological and hemodynamic evidences that increased arterial stiffness is a determinant of incident hypertension, and how the concept of Early Vascular Ageing can help understanding the relationship between arterIAL stiffness and prehypertension, is discussed.
Journal ArticleDOI
Erratum to: ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients
Massimo Volpe,Massimo Volpe,Alejandro de la Sierra,Reinhold Kreutz,Stéphane Laurent,Athanasios J. Manolis +5 more
TL;DR: In Fig. 2 of the article, when referring to Coronary artery disease with Grade 2 or Grade 3 hypertension the abbreviation ‘‘OLM’’ was used instead of ‘'OM'’ to indicate olmesartan, as defined in the footnote.
Journal ArticleDOI
How to estimate central pressure augmentation
TL;DR: It was not possible to deter-mine the amplitude of central PP and AIx reduction, and thus its influence on CV events, but the question arises whether the reduction in CV events is better predicted by central blood pressure (BP) (SBP, PP andAIx) than brachial BP.
Journal ArticleDOI
Perindopril 3.5 mg/amlodipine 2.5 mg versus renin-angiotensin system inhibitor monotherapy as first-line treatment in hypertension: a combined analysis.
TL;DR: In a large patient population, early administration of P3.5/A2.5 resulted in a significantly greater BP-lowering effect than perindopril, irbesartan or valsartan monotherapies after 1 month, and may reasonably be expected to lead to a reduced risk of cardiovascular events.